Nomograms Predict Survival Benefits of Radical Prostatectomy and Chemotherapy for Prostate Cancer with Bone Metastases: A SEER-based Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 23

PMID 36561516

Authors

Donglin Sun

Ao Lin

Zhun Sun

Shuqi Yang

Yuexin Sun

Anning Chen

Guojun Qian

Zhonghua Ji

Li Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to identify independent prognosis-associated factors of bone-metastatic prostate cancer. The nomograms were further developed to obtain indicators for the prognostic evaluation.

Methods: A total of 7315 bone-metastatic prostate cancer (PCa) patients from 2010 to 2016 were retrospectively collected from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were randomly divided into the training cohort (n=5,120) and test cohort (n=2,195) in a ratio of 7:3. Univariate and multivariate Cox regression models were applied to evaluate potential risk factors. A 1:1 propensity score matching (PSM) was further performed to decrease the confounding effect and re-evaluate the influence of radical prostatectomy and chemotherapy on prognosis. Combining these potential prognosis factors, the nomograms of cancer-specific survival (CSS) and overall survival (OS) at different times were established. C-indexes, calibration curves, and decision curves were developed to evaluate the discrimination, calibration, and clinical benefit of the nomograms.

Results: Eleven independent prognosis factors for CSS and twelve for OS were utilized to conduct the nomograms respectively. The C-indexes of nomograms for CSS and OS were 0.712 and 0.702, respectively. A favorable consistency between the predicted and actual survival probabilities was demonstrated by adopting calibration curves. Decision curves also exhibited a positive clinical benefit of the nomograms.

Conclusions: Nomograms were formulated successfully to predict 3-year and 5-year CSS and OS for bone-metastatic PCa patients. Radical prostatectomy and chemotherapy were strongly associated with the bone-metastatic PCa prognosis.

Citing Articles

Development and validation of two nomograms for predicting overall survival and Cancer-specific survival in prostate cancer patients with bone metastases: a population-based study.

Li B, Xing J, Wang Z, Gong Z, Wang Z, Xu A BMC Urol. 2023; 23(1):200.

PMID: 38049755 PMC: 10696723. DOI: 10.1186/s12894-023-01372-w.

References

Zhu X, Gou X, Zhou M . Nomograms Predict Survival Advantages of Gleason Score 3+4 Over 4+3 for Prostate Cancer: A SEER-Based Study. Front Oncol. 2019; 9:646. PMC: 6646708. DOI: 10.3389/fonc.2019.00646. View

Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R . Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011; 378(9809):2104-11. PMC: 3243932. DOI: 10.1016/S0140-6736(11)61095-7. View

Patel A, Stephenson A . Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?. Nat Rev Urol. 2011; 8(7):385-92. DOI: 10.1038/nrurol.2011.80. View

Petrylak D, Tangen C, Hussain M, Lara Jr P, Jones J, Taplin M . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15):1513-20. DOI: 10.1056/NEJMoa041318. View

Sun W, Jiang Y, Liu Y, Ma D, Shao Z . Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer. Oncotarget. 2016; 7(15):20496-506. PMC: 4991470. DOI: 10.18632/oncotarget.7975. View

Abdollah F, Sun M, Thuret R, Abdo A, Morgan M, Jeldres C . The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. Cancer Causes Control. 2011; 22(8):1085-95. DOI: 10.1007/s10552-011-9784-x. View

Iasonos A, Schrag D, Raj G, Panageas K . How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26(8):1364-70. DOI: 10.1200/JCO.2007.12.9791. View

Wallace A, Fiveash J, Williams C, Kvale E, Pisu M, Jackson B . Choosing Wisely at the End of Life: Use of Shorter Courses of Palliative Radiation Therapy for Bone Metastasis. Int J Radiat Oncol Biol Phys. 2018; 102(2):320-324. PMC: 9706505. DOI: 10.1016/j.ijrobp.2018.05.061. View

Zhong Y, Valderrama A, Yao J, Donga P, Bilir P, Neumann P . Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients. Value Health. 2018; 21(3):304-309. DOI: 10.1016/j.jval.2017.02.008. View

10.

Mahal B, Yang D, Wang N, Alshalalfa M, Davicioni E, Choeurng V . Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018; 74(2):146-154. PMC: 6615042. DOI: 10.1016/j.eururo.2018.01.043. View

11.

Nuhn P, de Bono J, Fizazi K, Freedland S, Grilli M, Kantoff P . Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur Urol. 2018; 75(1):88-99. DOI: 10.1016/j.eururo.2018.03.028. View

12.

Huang T, Zhou G, Dong C, Wang L, Luan Y, Ye J . Marital status independently predicts prostate cancer survival in men who underwent radical prostatectomy: An analysis of 95,846 individuals. Oncol Lett. 2018; 15(4):4737-4744. PMC: 5840566. DOI: 10.3892/ol.2018.7964. View

13.

Jiang W, Yuan P . Development and validation of prognostic nomograms for patients with metastatic prostate cancer. Int Urol Nephrol. 2019; 51(10):1743-1753. DOI: 10.1007/s11255-019-02224-z. View

14.

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

15.

Shou J, Zhang Q, Wang S, Zhang D . The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study. Prostate. 2018; 78(7):491-497. DOI: 10.1002/pros.23492. View

16.

Cuzick J, Thorat M, Andriole G, Brawley O, Brown P, Culig Z . Prevention and early detection of prostate cancer. Lancet Oncol. 2014; 15(11):e484-92. PMC: 4203149. DOI: 10.1016/S1470-2045(14)70211-6. View

17.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T . EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016; 71(4):630-642. DOI: 10.1016/j.eururo.2016.08.002. View

18.

Logothetis C, Morris M, Den R, Coleman R . Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018; 37(1):189-196. PMC: 5801387. DOI: 10.1007/s10555-017-9719-4. View

19.

Marshall S, Taneja S . Focal therapy for prostate cancer: The current status. Prostate Int. 2015; 3(2):35-41. PMC: 4494637. DOI: 10.1016/j.prnil.2015.03.007. View

20.

Steele C, Li J, Huang B, Weir H . Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017; 123 Suppl 24:5160-5177. PMC: 6077841. DOI: 10.1002/cncr.31026. View